Companies › Biocodex
2 active drug programs in 40 registered trials: 20 Phase 4, 12 Phase 3, 6 Phase 2, 2 Phase 1; Gastroenterology, Cardiovascular, Infectious disease, Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Amoxicillin (I-745) Bacterial penicillin-binding protein inhibitor | – | Phase 4 | Erythema Migrans of Lyme Disease; Rupture of Membranes; Delayed Delivery (Following Spontaneous Rupture); Helicobacter Pylori; Acute Coronary Syndrome … | Dec 2026 |
| Saccharomyces Boulardii CNCM I-745 Probiotic microorganism | – | Phase 3 | IBS (Irritable Bowel Syndrome) | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04047849 | Amoxicillin (I-745) | Phase 4 | Rupture of Membranes; Delayed Delivery (Following Spontaneous Rupture) | Other | Jul 2021 |
| NCT07122024 | Amoxicillin (I-745) | Phase 4 | Helicobacter Pylori | Infectious disease | Aug 2025 |
| NCT06734260 | Amoxicillin (I-745) | Phase 3 | Helicobacter Pylori Eradication Rate | Infectious disease | Nov 2025 |
| NCT04728516 | Amoxicillin (I-745) | Phase 4 | Acute Coronary Syndrome | Infectious disease | Jun 2026 |
| NCT07168434 | Saccharomyces Boulardii CNCM I-745 | Phase 3 | IBS (Irritable Bowel Syndrome) | Gastroenterology | Oct 2026 |
| NCT05957432 | Amoxicillin (I-745) | Phase 2 | Helicobacter Pylori Infection | Infectious disease | Nov 2026 |
| NCT06929962 | Amoxicillin (I-745) | Phase 4 | Helicobacter Pylori Infection | Infectious disease | Dec 2026 |
| NCT07451171 | Amoxicillin (I-745) | Phase 2 | Small Intestine Bacterial Overgrowth | Infectious disease | Dec 2026 |
| NCT06451913 | Amoxicillin (I-745) | Phase 4 | Erythema Migrans of Lyme Disease | Infectious disease | Dec 2026 |
| NCT06303128 | Amoxicillin (I-745) | Phase 3 | Penicillin Allergy | Other | Dec 2026 |
| NCT07894016 | Amoxicillin (I-745) | Phase 4 | Wisdom Tooth Removal | Other | Dec 2026 |
| NCT07556991 | Amoxicillin (I-745) | Phase 2 | Chronic Subdural Hematomas | Cardiovascular | Dec 2026 |
| NCT06823154 | Amoxicillin (I-745) | Phase 1 | Allergy Amoxicillin | Other | Dec 2026 |
| NCT06709196 | Amoxicillin (I-745) | Phase 4 | Cystectomy | Oncology | Jan 2027 |
| NCT06921213 | Amoxicillin (I-745) | Phase 2 | Syphilis, Congenital | Infectious disease | Mar 2027 |
| NCT06229288 | Amoxicillin (I-745) | Phase 3 | Community-acquired Pneumonia | Respiratory | May 2027 |
| NCT03031210 | Amoxicillin (I-745) | Phase 2 | Community-acquired Pneumonia | Respiratory | Jun 2027 |
| NCT06126731 | Amoxicillin (I-745) | Phase 1 | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Oncology | Jun 2027 |
| NCT05846399 | Amoxicillin (I-745) | Phase 4 | Cat Bite | Infectious disease | Jul 2027 |
| NCT06771492 | Amoxicillin (I-745) | Phase 3 | MSK Conditions | Other | Aug 2027 |
| NCT05224401 | Amoxicillin (I-745) | Phase 3 | Urinary Tract Infections | Infectious disease | Sep 2027 |
| NCT06929702 | Amoxicillin (I-745) | Phase 4 | Amoxicillin-clavulanate | Other | Oct 2027 |
| NCT07582549 | Amoxicillin (I-745) | Phase 3 | Chronic Cough | Other | Dec 2027 |
| NCT03966014 | Amoxicillin (I-745) | Phase 3 | Erythema Migrans | Infectious disease | Dec 2027 |
| NCT03966014 | Amoxicillin (I-745) | Phase 3 | Erythema Migrans | Infectious disease | Dec 2027 |
| NCT06877351 | Amoxicillin (I-745) | Phase 3 | Syphilis Acquired | Infectious disease | Jan 2028 |
| NCT07492134 | Amoxicillin (I-745) | Phase 2 | Acute Uncomplicated Diverticulitis | Gastroenterology | Apr 2028 |
| NCT06020716 | Amoxicillin (I-745) | Phase 4 | Protracted Bacterial Bronchitis | Infectious disease | Apr 2028 |
| NCT06494072 | Amoxicillin (I-745) | Phase 4 | Community Acquired Pneumonia in Children | Respiratory | May 2028 |
| NCT05761080 | Amoxicillin (I-745) | Phase 4 | Laparoscopic Appendectomy | Gastroenterology | Jun 2028 |
| NCT07896239 | Amoxicillin (I-745) | Phase 4 | Surgical Wound Infection | Infectious disease | Sep 2028 |
| NCT06076304 | Amoxicillin (I-745) | Phase 4 | Sinus Infection | Infectious disease | Oct 2028 |
| NCT07275580 | Amoxicillin (I-745) | Phase 4 | Autoimmune Rheumatic Diseases | Infectious disease | Jun 2029 |
| NCT07576959 | Amoxicillin (I-745) | Phase 3 | HELICOBACTER PYLORI INFECTIONS | Infectious disease | Dec 2030 |
| NCT07730814 | Amoxicillin (I-745) | Phase 4 | Acute Otitis Media (AOM) | Other | Dec 2031 |
| NCT07730814 | Amoxicillin (I-745) | Phase 4 | Acute Otitis Media (AOM) | Other | Dec 2031 |
| NCT07732699 | Amoxicillin (I-745) | Phase 4 | ACUTE SINUSITIS | Respiratory | Dec 2031 |
| NCT07732699 | Amoxicillin (I-745) | Phase 4 | ACUTE SINUSITIS | Respiratory | Dec 2031 |
| NCT02047994 | Amoxicillin (I-745) | Phase 4 | Helicobacter Pylori Infections | Oncology | Dec 2033 |
| NCT01678027 | Amoxicillin (I-745) | Phase 3 | Gastric Cancer | Oncology | Dec 2035 |
No annotated target.
–
Getz Pharma Dr. F. Köhler Chemie Albireo, an Ipsen Company Norgine Elgan Pharma
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.